Fielder Capital Group LLC Buys 102 Shares of AbbVie Inc. $ABBV

Fielder Capital Group LLC boosted its holdings in AbbVie Inc. (NYSE:ABBV) by 4.2% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,516 shares of the company’s stock after buying an additional 102 shares during the period. Fielder Capital Group LLC’s holdings in AbbVie were worth $467,000 as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in the business. Curio Wealth LLC increased its position in AbbVie by 10,466.7% in the 2nd quarter. Curio Wealth LLC now owns 317 shares of the company’s stock worth $59,000 after buying an additional 314 shares during the period. Boothe Investment Group Inc. bought a new position in AbbVie in the 2nd quarter worth approximately $5,420,000. Leelyn Smith LLC increased its position in AbbVie by 1.7% in the 2nd quarter. Leelyn Smith LLC now owns 18,206 shares of the company’s stock worth $3,379,000 after buying an additional 299 shares during the period. Hobart Private Capital LLC bought a new position in AbbVie in the 2nd quarter worth approximately $200,000. Finally, Ranch Capital Advisors Inc. increased its position in AbbVie by 1.7% in the 2nd quarter. Ranch Capital Advisors Inc. now owns 10,140 shares of the company’s stock worth $1,882,000 after buying an additional 168 shares during the period. 70.23% of the stock is owned by institutional investors.

AbbVie Trading Down 0.1%

Shares of ABBV opened at $228.06 on Friday. The company has a quick ratio of 0.61, a current ratio of 0.74 and a debt-to-equity ratio of 44.14. AbbVie Inc. has a 12-month low of $163.81 and a 12-month high of $244.81. The firm has a market capitalization of $402.87 billion, a PE ratio of 108.60, a price-to-earnings-growth ratio of 1.44 and a beta of 0.51. The stock’s fifty day simple moving average is $220.69 and its 200-day simple moving average is $198.94.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Thursday, July 31st. The company reported $2.97 EPS for the quarter, missing analysts’ consensus estimates of $3.24 by ($0.27). The company had revenue of $15.42 billion during the quarter, compared to the consensus estimate of $14.93 billion. AbbVie had a net margin of 6.45% and a return on equity of 699.66%. The company’s revenue for the quarter was up 6.6% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.65 EPS. As a group, research analysts predict that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, November 14th. Shareholders of record on Wednesday, October 15th will be issued a $1.64 dividend. This represents a $6.56 annualized dividend and a dividend yield of 2.9%. The ex-dividend date is Wednesday, October 15th. AbbVie’s dividend payout ratio is 312.38%.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on ABBV shares. Daiwa America raised AbbVie from a “hold” rating to a “strong-buy” rating in a report on Thursday, August 7th. HSBC set a $225.00 price objective on AbbVie in a report on Thursday, October 2nd. Raymond James Financial reissued an “outperform” rating and set a $250.00 price objective (up previously from $236.00) on shares of AbbVie in a report on Friday, October 17th. Wells Fargo & Company lifted their price objective on AbbVie from $240.00 to $260.00 and gave the stock an “overweight” rating in a report on Friday, September 12th. Finally, Hsbc Global Res lowered AbbVie from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 1st. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and nine have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $234.80.

Insider Activity

In other AbbVie news, EVP Azita Saleki-Gerhardt sold 42,370 shares of the stock in a transaction dated Tuesday, August 12th. The stock was sold at an average price of $198.42, for a total value of $8,407,055.40. Following the completion of the sale, the executive vice president directly owned 177,292 shares in the company, valued at $35,178,278.64. This represents a 19.29% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Nicholas Donoghoe sold 13,295 shares of the stock in a transaction dated Tuesday, August 5th. The stock was sold at an average price of $198.51, for a total value of $2,639,190.45. Following the transaction, the executive vice president owned 58,247 shares of the company’s stock, valued at approximately $11,562,611.97. The trade was a 18.58% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.25% of the stock is owned by corporate insiders.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.